ID   FU-DDLS-1
AC   CVCL_M815
SY   FU-DD-LS1; Fukuoka University-DeDifferentiated LipoSarcoma-1
DR   cancercelllines; CVCL_M815
DR   Cosmic; 2307718
DR   Cosmic; 2800520
DR   GEO; GSM529099
DR   Progenetix; CVCL_M815
DR   Wikidata; Q54835233
RX   PubMed=12579306;
RX   PubMed=17354236;
RX   PubMed=22911243;
RX   PubMed=24726063;
RX   PubMed=26643872;
CC   Population: Japanese.
CC   Doubling time: ~52 hours (PubMed=12579306).
CC   Omics: Variations; SNP array analysis.
DI   NCIt; C3704; Dedifferentiated liposarcoma
DI   ORDO; Orphanet_99970; Dedifferentiated liposarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 10-04-25; Version: 15
//
RX   PubMed=12579306; DOI=10.3892/ijo.22.3.535;
RA   Nishio J., Iwasaki H., Ishiguro M., Ohjimi Y., Fujita C., Ikegami H.,
RA   Ariyoshi A., Naito M., Kaneko Y., Kikuchi M.;
RT   "Establishment of a novel human dedifferentiated liposarcoma cell
RT   line, FU-DDLS-1: conventional and molecular cytogenetic
RT   characterization.";
RL   Int. J. Oncol. 22:535-542(2003).
//
RX   PubMed=17354236; DOI=10.1002/ijc.22643;
RA   Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G.,
RA   Myklebost O.;
RT   "Potential for treatment of liposarcomas with the MDM2 antagonist
RT   Nutlin-3A.";
RL   Int. J. Cancer 121:199-205(2007).
//
RX   PubMed=22911243; DOI=10.1155/2012/148614; PMCID=PMC3403520;
RA   Stratford E.W., Castro R., Daffinrud J., Skarn M., Lauvrak S.,
RA   Munthe E., Myklebost O.;
RT   "Characterization of liposarcoma cell lines for preclinical and
RT   biological studies.";
RL   Sarcoma 2012:148614.1-148614.9(2012).
//
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33; PMCID=PMC4022359;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
//
RX   PubMed=26643872; DOI=10.18632/oncotarget.6464; PMCID=PMC4767443;
RA   Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K.,
RA   Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U.,
RA   Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K.,
RA   Tanaka H., Miyano S., Myklebost O., Yang H.H., Dugas M.,
RA   Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S.,
RA   Koeffler H.P.;
RT   "Genomic landscape of liposarcoma.";
RL   Oncotarget 6:42429-42444(2015).
//